Markers of Endothelial and in Vivo Platelet Activation in Patients with Essential Thrombocythemia and Polycythemia Vera

International Journal of Hematology

Volumn 79, Issue 3, 2004, Pages 253-259

  Karakantza, Marina ^a   Giannakoulas, Nikolaos C ^b   Zikos, Panagiotis ^c   Sakellaropoulos, George ^a   Kouraklis, Alexandra ^b   Aktypi, Anthi ^c   Metallinos, Ioannis C ^a   Theodori, Eleni ^a   Zoumbos, Nicholas C ^b   Maniatis, Alice ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c District Hospital

Author keywords

Endothelial activation; Essential thrombocythemia; Platelet activation; Polycythemia vera; Thrombosis

Indexed keywords

ANGIOGENIC FACTOR; CD63 ANTIGEN; PADGEM PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ENDOTHELIUM; ERYTHROMELALGIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

EID: 2442555214     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.E0316     Document Type: Article

References (42)

1. Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost. 1997;78:617-621.
2. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984;64:1-12.
3. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
4. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13:150-154.
5. Lahuerta-Palacios JJ, Bornstein R, Fernández-Debora FJ, et al. Controlled and uncontrolled thrombocytosis: its clinical role in essential thrombocythemia. Cancer. 1988;61:1207-1212.
6. Pearson TC. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera. Semin Thromb Hemost. 1997;23:433-439.
7. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol. 1993;83:198-203.
8. Tefferi A. Recent progress in the pathogenesis and management of essential thrombocythemia. Leuk Res. 2001;25:369-377.
9. Broughton BJ, Allington MJ, King A. Platelet and plasma β-thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol. 1978;40:125-132.
10. Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemost. 1982;48:41-45.
11. Wehmeier A, Tschöpe D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res. 1991;61:271-278.
12. Zahavi J, Zahavi M, Firsteter E, Frish B, Turleanu R, Rachmani R. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol. 1991;47:326-332.
13. Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost. 1993;70:736-742.
14. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995;74:1225-1230.
15. Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res. 1999;96:191-196.
16. Raszeja-Specht A, Skibowska A, Bieniaszewska M, Szutowicz A. Relationships between thrombohemorrhagic complications and platelet function in patients with essential thrombocythaemia. Am J Hematol. 2001;68:32-36.
17. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2003;108:139-145.
18. Friedenberg WR, Roberts RC, David DE. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am J Hematol. 1992;40:283-289.
19. van Genderen PJJ, Lucas IS, van Strik R, et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost. 1996;76:333-338.
20. Musolino C, Alonci A, Allegra A, et al. Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications. Am J Hematol. 1998;57:109-112.
21. Musolino C, Alonci A, Bellomo G, et al. Markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology. 2000;4:397-402.
22. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96: 4261-4266.
23. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol. 1986;23:132-143.
24. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the polycythemia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29-39.
25. Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol. 1996;143:1257-1265.
26. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132-1136.
27. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood. 1990;75:128-138.
28. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Clin Rev Oncol Hematol. 1995;20:203-222.
29. Schmitz G, Rothe G, Ruf A, et al. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998;79: 885-896.
30. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br J Haematol. 1999; 104:886-892.
31. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863-866.
32. Michiels JJ. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. Clin Appl Thromb Hemost. 1999;5:247-251.
33. Usuki K, Iki S, Endo M, et al. Influence of thrombopoietin on platelet activation in myeloproliferative disorders. Br J Haematol. 1997;97:530-537.
34. Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998;80:171-175.
35. Salgado R, Benoy I, Bogers J, et al. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis. 2001;4:37-43.
36. Verheul HMW, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MFBG, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 2000;96:4216-4221.
37. Di Raimondo F, Palumbo GA, Molica S, Giustolisi R. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol. 2001; 106:177-183.
38. Musolino C, Calabro' L, Bellomo G, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol. 2002;69:159-163.
39. McEver RP. Adhesive interactions of leucocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001;86:746-756.
40. Kaplar M, Kappelmayer J, Kiss S, Szabo K, Udvardy M. Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts. Platelets. 2000;11:183-184.
41. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leucocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001; 66:143-151.
42. van Genderen PJJ, Prins FJ, Michiels JJ, Schrör K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol. 1999;104:438-441.